CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
disruption in lymphocytes was only approximately 5%, which indicates the need for further research into this approach. (Funded by the Beijing Municipal Science and Technology Commission and others; ClinicalTrials.gov number, NCT03164135.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Subsequent experiments showed that p53 inactivation can be controlled or avoided through protocol optimization 47,107 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [107]
Citations
Cites
1 retracted
CCR5-∆32 is deleterious in the homozygous state in humans
Wei, X., & Nielsen, R. (2019) · Nature Medicine · doi:10.1038/s41591-019-0459-6 · Cited by 75
RetractedIdentification of a major co-receptor for primary isolates of HIV-1
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Marzio, P. D., Marmon, S., Sutton, R. E., Hill, C. M., et al. (1996) · Nature · doi:10.1038/381661a0 · Cited by 3,641
Self-citationSamson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C.-M., Saragosti, S., Lapouméroulie, C., Cognaux, J., Forceille, C., et al. (1996) · Nature · doi:10.1038/382722a0 · Cited by 2,886
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müßig, A., Allers, K., Schneider, T., Hofmann, J., Kücherer, C., Blau, O., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802905 · Cited by 1,837
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Komor, A. C., Badran, A. H., & Liu, D. R. (2017) · Cell · doi:10.1016/j.cell.2016.10.044 · Cited by 1,013
Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
Aiuti, A., Cattaneo, F., Galimberti, S., Benninghoff, U., Cassani, B., Callegaro, L., Scaramuzza, S., Andolfi, G., Mirolo, M., Brigida, I., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805817 · Cited by 1,007
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases
Perez, E. E., Wang, J., Miller, J. C., Jouvenot, Y., Kim, K. A., Liu, O., Wang, N., Lee, G., Bartsevich, V. V., Lee, Y.-L., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1410 · Cited by 999
Self-citationCRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
Cited by
Items 401–468 of 468
DNA Repair Pathways in the Context of Therapeutic Genome Editing
Wimberger, S., Akrap, N., & Taheri‐Ghahfarokhi, A. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch13
(2019) · Reactions Weekly · doi:10.1007/s40278-019-71127-5
Romito, M., Juillerat, A., Kok, Y. L., Hildenbeutel, M., Rhiel, M., Andrieux, G., Geiger, J. P., Rudolph, C., Mussolino, C., Duclert, A., et al. (2020) · doi:10.22541/au.158990011.12602649
“This is in line with a recently published case report confirming that a CCR5 knockout frequency of 5% in the T cell compartment is not sufficient to achieve clinical benefit [41].”
ResultAraújo, A. T. M., & Verdival, R. (2020) · Revista da Faculdade Mineira de Direito · doi:10.5752/p.2318-7999.2020v23n46p161-186
Biomarkers for Cancer Drug Development
Rehman, G. (2022) · Springer eBooks · doi:10.1007/978-981-16-5759-7_3
The HIV Reservoir and Cure and Remission Strategies
Gandhi, R. T., Jülg, B. D., Jilg, N., Jakharia, N., & Talwani, R. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780197576595.003.0026
Deng, H., Liu, Y., & Sun, S. (2022) · Wiley eBooks · doi:10.1002/9781119692799.ch12
Self-citationRetroviruses: Reversing the dogma of life - A review
Shobha, P., Andrew, M., Shrina, P., Aayushi, P., Gregory, W., Kane, S., Lookfong, N. A., Abigayle, N., Xiuli, S., & Sairam, R. V. (2022) · Journal of Clinical Microbiology and Biochemical Technology · doi:10.17352/jcmbt.000051 · Cited by 1
CRISPR and gene editing in HIV therapy: A scoping review
Universidad de La Sabana, F. D. M., & Tuta-Quintero, E. (2023) · Gaceta Médica de Caracas · doi:10.47307/gmc.2023.131.1.18
Zhao, W., Li, J., Wang, X., Xu, W., Gao, B., Xiang, J., Hou, Y., Liu, W., Wu, J., Qi, Q., et al. (2023) · MedComm · doi:10.1002/mco2.356 · Cited by 1
“33 Unlike the CCR5 receptor, which has a Delta32 deletion heterozygous allele frequency of ∼ 10% in Europe and thus appears dispensable, most viral-related host factors have important physiological functions.”
Self-citationThe HIV Reservoir and Cure and Remission Strategies
Jülg, B. D., Gandhi, R. T., & Jilg, N. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197679098.003.0019
Gene surgery as a potential treatment option for Nephropathic Cystinosis in vitroPreprint
Garví, E. S., Faria, J., Casellas, C. P., Thijssen, S., Wubbolts, E. J., Jamalpoor, A., Harrison, P., Masereeuw, R., & Janssen, M. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.01.565117
“Additionally, this revolutionary technology has been successfully tested in humans to treat β -thalassemia, sickle cell disease [25] and HIV-1 [26].”
BackgroundWang, M., Zhang, J. L., Bian, Z., Cao, W. J., Wan, D., & Jiang, E. (2023) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2023.09.014
Júnior, Y. F. D. M., & da Costa, R. S. L. (2024) · Revista Foco · doi:10.54751/revistafoco.v17n1-088
Tang, M. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/rd5m1c10
“[ 18].”
Gene Editing Approaches for Haematological Disorders
Ferrari, S., & Canarutto, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00053-6 · Cited by 1
Sécurisation de la thérapie génique par CRISPR-Cas9 dans les pathologies du globule rouge
Boutin, J. (2021) · theses.fr (ABES) · doi:10.70675/aa1d0b59z401cz4506zacd4z39e9fd3c090b
Recent Advances and Effective Curative Interventions Toward an Hiv/Aids Functional CurePreprint
Jiang, L., Pu, Y., Zhao, M., Zang, J., & Zhang, J. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4896481
Prospects of hematopoietic stem cell transplantation for patients with HIV infection
Маратовна, Г. М., Chernysheva, O. O., Tsyganova, E. V., & Dudina, G. A. (2024) · Infectious diseases News Opinions Training · doi:10.33029/2305-3496-2024-13-2-74-85
Applications of CRISPR technology
Du, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23865-9.00003-4
He, X., Yang, N., Sun, T., Xue, J., Zhang, X., Chu, J., Li, L., Liu, H., Lü, G., Bi, X., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-5767015/v1
Current trends and future of gene-cell immunotherapy in the treatment of HIV infection
Faenko, A. P., Dudina, G. A., Mabudzade, C. K., & Ogannisyan, A. A. (2025) · Oncohematology · doi:10.17650/1818-8346-2025-20-2-115-125
Imran, S. A., Sultan, H. M., Zubair, M., Ghazanfar, S., Islam, A., Rahaman, S. M., & Ashique, S. (2025) · Current Cancer Therapy Reviews · doi:10.2174/0115733947375292250526055904
Hematopoietic cell transplantation and cellular therapy
Khan, I., Shah, N. N., & Ulrickson, M. L. (2022) · doi:10.1182/ashsap8.chapter14
Advancement of Synthetic Biology Strategies for Bioinspired Regenerative Medicine
Khoshnevisan, K., Maleki, H., & Baharifar, H. (2025) · Springer eBooks · doi:10.1007/978-3-031-87744-5_14 · Cited by 1
The HIV Reservoir and Cure and Remission Strategies
Jülg, B. D., Gandhi, R. T., & Jilg, N. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197812631.003.0018
Sandhu, A. S., Anas, M., Eisha, Shoukat, S., Talha, M., Chorahi, M. U., Arif, M. I., & Arbab, Q. U. A. (2025) · Indus journal of bioscience research. · doi:10.70749/ijbr.v3i6.1754
CRISPR-Cas Gene Editing Approaches for HIV Reservoir Elimination and Functional Cure Strategies
Anitah, M. (2025) · NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY · doi:10.59298/nijpp/2025/636468
“While technically complex, this strategy permits rigorous quality control and reduces systemic exposure [22].”
CRISPR-Cas9 in acute myeloid leukaemia: Current state-of-art and future perspectives
Zingarelli, F., Nanni, J., Cristiano, G., Zannoni, L., & Curti, A. (2025) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2025.102582
CRISPR/Cas9: the future of human gene editing
Zulkifli, N. D., Sani, S. B. M., Wong, C. H., Mahadzan, M., Suhimi, M. H. A., Zulkifli, N., & Das, K. T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33947-9.00009-8
Liu, Z., Liang, J., Chen, S., Wang, K., Liu, X., Liu, B., Xia, Y., Guo, M., Zhang, X., Sun, G., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12629224
Liu, Z., Liang, J., Chen, S., Wang, K., Liu, X., Liu, B., Xia, Y., Guo, M., Zhang, X., Sun, G., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12629227
Liu, Z., Liang, J., Chen, S., Wang, K., Liu, X., Liu, B., Xia, Y., Guo, M., Zhang, X., Sun, G., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12629221
Ponta, S., Bonato, A., Neidenbach, P., Bruhin, V. F., Laurent, A. E., Applegate, L. A., Zenobi‐Wong, M., & Barreto, G. (2024) · Figshare · doi:10.6084/m9.figshare.26691586
Liang, J., Teng, P., Xiao, W., He, G., 宋其芳, Zhang, Y., Peng, B., Li, G., Hu, L., Cao, D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16590462
Self-citationPrieto Blanque, M. (2024) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Creation of TatDE rLNPs for the Excision of Integrated HIV-1 Proviral DNA
Hasan, M. (2023) · DigitalCommons@UNMC
Happi Mbakam, C. (2023) · Corpus Université Laval (Université Laval)
Chen, M. (2023) · eScholarship@McGill (McGill) · doi:10.82308/20819
Cellular and Molecular Mechanisms of Hematopoietic Stem Cell Regenerative Capacity Throughout Life
Worthington, A. K. (2023) · eScholarship (California Digital Library)
Edición Genética de las Células Madre con CRISPR-Cas: Avances en la Medicina Regenerativa
Sánchez, G. P. V., Villacís, I. S., & Ocaña, T. V. (2025) · Revista Científica Multidisciplinar G-nerando · doi:10.60100/rcmg.v6i2.894
Stem cell–based strategies for HIV-1 remission: Emerging frontiers and translational challenges
Chatterjee, A. (2025) · Archives of Stem Cell and Therapy · doi:10.46439/stemcell.6.025
Yaguache, K. M. T. (2025) · Polo del Conocimiento · doi:10.23857/pc.v10i12.10882
CRISPR-Cas9 CCR5 Gene Editing for Functional Cure in HIV-Infected Individuals
Evelyn, M. K. (2026) · IAA Journal of Applied Sciences · doi:10.59298/iaajas/2026/14115
Aliev, T. I., Imatdinov, A. R., Prudnikova, E. Y., & Иматдинов, И. Р. (2026) · Molecular Biology · doi:10.1134/s0026893325700591
CRISPR-Cas9-based strategies for enhanced targeted integration
Lacombe, L. (2024) · theses.fr (ABES) · doi:10.70675/9c9d279dz512az4b72z8322zea205cef9b67 · Cited by 1
Xu, L., Wang, J., Zhao, W., Wang, Y., Hu, Y., Li, Y., Lai, W., Yong, J., Gao, C., Liu, D., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70499
Self-citationArrayed dual-gRNA CRISPR screening platform for C9orf72 repeat expansion excision in patient iPSCs
Arogundade, O. A., Lam, K. J. K., Brown, K. A., Jain, T., Issagholian-Lewin, P. O., Huang, C., Hudson, T. R., Briseno, K., Wyman, S. K., Krishnappa, N., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201741
“The top 5 ꞌ gRNAs 3, 4, 11, 12, and 13 when paired with 3 ꞌ gRNAs other than C (A, B, and D) had reduced excision rates by 15%–56%, indicating that excision efficiency of a gRNA pair can be promoted or limited by individual gRNAs in the pair.”
Kumar, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-7688-3_6
CCR5 and Its Mutation in HIV Infection, and the Therapeutic Approach with CRISPR-Cas9
Shibuya, N. (2026) · International journal of high school research · doi:10.36838/ijhsr87.210
CRISPR-Cas9 in Rare Genetic Disease Treatment: Mechanisms, Applications, and Future Perspectives
Sharma, A. (2026) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-35711
Genetics and Pediatric Rheumatic Diseases
Ombrello, M. J., & Prahalad, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11980-4.00006-4
Font, L. F., Jin, D., Figg, J., Francis, C. P., Long-James, K., Drake, J., Reid, A., Love, C., McDonald, B., Hilferty, D., et al. (2026) · Journal of Translational Research · doi:10.1080/29947448.2026.2660423
Chen, R., Xing, C., Limei, L., Huan, L., Liping, X., Huang, D., Liu, Y., Zhou, D., Weilong, Y., Zhou, S., et al. (2026) · Translational research · doi:10.1016/j.trsl.2026.06.015
Self-citationCRISPRing through time: How cutting-edge technology is revolutionizing life sciences and medicine
Banik, I., & Coppé, J. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103003
Gene editing of hematopoietic stem cells: applications and advances
Li, Q., Wang, H., He, Y., Hong, G., & Bao, G. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04251-w
“However, during the analytical treatment interruption period, the patient experienced relatively rapid viral rebound [84], which indicated that the rate of expansion of the edited cells was insufficient to suppress newly occurring viral replication.”
Weigand, L., Herkt, S. C., Voges, M., Beschorner, N., Friedrich, J., Rieger, D., Karpova, D., Weseloh, B., Vogel, L. A., Chemnitz, J., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-64038-1
“…hematopoietic stem cell donor deficient for CCR5, despite the modest success rate of curing HIV even when it is achieved, several groups sought to cure HIV by inducing CCR5 deficiency with zinc-finger-nucleases (ZFN), transcription activator-like effector nucleases (TALEN), or CRISPR/Cas 20–24 .”
Fraser, M. E., Martin, A., Mulvahill, J., Dawson, J., Mohammed, A., McDonald, T., Cisse, G.-I., Rivera-Luna, A., & Fraser, M. J. (2026) · Virology · doi:10.1016/j.virol.2026.111044
Iqbal, U., Khalid, K., Shaltout, M., Yükselten, Y., & Sutton, R. E. (2026) · Viruses · doi:10.3390/v18090972
Recent Applications of mRNA-Based Technology for Disease Therapy
Jun, Z., Xiang, W., Yang, S., Qiang, H., Wei, J., Wang, H., Jia, Z., Yuting, L., & Liu, X. (2026) · Synthetic biology and engineering · doi:10.70322/sbe.2026.10014
Overview of Delivery Methods for Gene Editing
BÜTÜNER, B. D. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5547-4_6
Andrade, R. W. D. S., & Helou, G. M. R. (2026) · Revista Direitos Fundamentais & Democracia
Deng, Z., He, X.-Y., Wang, X., Zheng, Y., Su, B., & Zheng, H. (2026) · Science China Life Sciences · doi:10.1007/s11427-026-3444-x
Self-citationNovel Technologies and Clinical Breakthroughs: The Evolving Landscape of Gene Therapy in China
Li, J., Deng, Y., Ma, J., Huang, M., & Deng, H. (2026) · Human Gene Therapy · doi:10.1177/10430342261498531
Self-citationBorovikova, S. E., Tvorogova, A. V., Shepelev, M. V., & Kruglova, N. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219695
Overview of Cellular and Gene Therapy Products
(2026) · Elsevier eBooks · doi:10.1016/b978-0-443-48612-8.00001-4
Metadata
- Authors
- Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., Zhang, B., Zhao, L., Hu, L., Ning, H., Zhang, Y., Deng, K., Liu, L., Lu, X., Zhang, T., Xu, J., Li, C., Wu, H., Deng, H., & Chen, H.
- Affiliations
- Peking University (CN)
- Capital Medical University (CN)
- Sun Yat-sen University (CN)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-09-26
- Volume
- 381
- Issue
- 13
- Pages
- 1240-1247
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2972390440
- Cited by
- 454
- References
- 27
- Citations by year
- 2026: 34 · 2025: 52 · 2024: 57 · 2023: 45 · 2022: 77 · 2021: 87 · 2020: 89 · 2019: 13
- FWCI
- 21.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Key Research and Development Program of China (2017YFA0103000)
- Beijing Municipal Science and Technology Commission (D171100000517004)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- CRISPR gene editing, hematopoietic stem cells, HIV, acute lymphoblastic leukemia, gene therapy
- MeSH terms
- Gene Editing, Adult, Blood Cell Count, Hematopoietic Stem Cells, Humans, Male, HIV-1, HIV Infections, Hematopoietic Stem Cell Transplantation, CD4 Lymphocyte Count, Viral Load, Receptors, CCR5, Anti-Retroviral Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.